Comparing Results for 80 mg versus 160 mg Osimertinib in Advanced EGFR+ NSCLC

May 16, 2019
Myung-Ju Ahn, MD

Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib with a 160 mg dose in patients with <em>EGFR</em>-positive advanced non&ndash;small cell lung cancer with leptomeningeal metastases.

Myung-Ju Ahn, MD, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, discusses the findings from the AURA LM study, which compared an 80 mg dose of osimertinib (Tagrisso) with a 160 mg dose in patients withEGFR-positive advanced non—small cell lung cancer with leptomeningeal metastases (LM).

Data was compared in an analysis from 4 studies in the AURA program, says Ahn. The LM response rate was 55%, and the LM progression-free survival was 11.1 months. The median overall survival was 18.8 months.